GcMAF

GcMAF, or Gc protein-derived macrophage activating factor, is described in the literature as a macrophage-activating derivative of vitamin D-binding protein. The cancer theory centers on tumor-associated alpha-N-acetylgalactosaminidase, commonly called nagalase, which is claimed to deglycosylate vitamin D-binding protein and impair endogenous macrophage activation.

The research base contains several distinct layers. Preclinical papers report tumoricidal macrophage activity, anti-angiogenic effects, tumor growth inhibition in mice, breast cancer cell effects, and possible interaction with photodynamic therapy. Human cancer reports include the well-known Yamamoto papers, which claimed striking responses in breast, colorectal, and prostate cancer using weekly 100 ng GcMAF and nagalase monitoring. The breast and colorectal cancer papers were formally retracted, and critics identified major reliability problems; supporters dispute the interpretation of those events and argue the retractions may not settle the scientific question. A later retrospective report in advanced cancers was open-label and uncontrolled, but it is part of the historical record and should be reviewed alongside the rest of the literature.

Regulatory and patient-safety records are also part of this topic. UK and European reporting around Immuno Biotech / First Immune and David Noakes describes unlicensed manufacture and sale of GcMAF as a cancer cure. Cancer Research UK, the Anticancer Fund, WebMD, MHRA, BMJ, and government sources warn against relying on GcMAF as an approved cancer treatment. These sources are included as documentation of the controversy, not as the database taking a final position on the biology or on the motivations behind the retractions.

• The macrophage-activation theory and nagalase literature can be tracked for research context.
• Some preclinical or small human reports exist for review.

CONS

• Cancer efficacy is unproven and the field includes disputed, retracted, or regulatory-problematic material.
• Product purity, dosing, immune effects, and infection risks are major concerns.
• Should not replace evidence-based care.